By: Jordyn Savap From: targetedonc.com The phase 3 PRESERVE 2 trial (NCT04799249) of trilaciclib (Cosela) in combination with gemcitabine and carboplatin for the first-line treatment of metastatic triple-negative breast cancer (TNBC) has been recommended to continue to the final analysis by the independent data monitoring committee, according to G1 Therapeutics, Inc.1 No concerns regarding safety were expressed by the data …
Exercise program improves quality of life for patients with metastatic breast cancer
By: Matthew Shinkle From: healio.com Key takeaways: Results showed improved quality of life and reduced fatigue after the exercise program. More research is needed to design a safe exercise program for those with unstable bone metastases. SAN ANTONIO — Patients with metastatic breast cancer who take part in a supervised, structured exercise program during palliative treatment may experience improved quality …
Metastatic breast cancer treatments have aided decline in deaths, Stanford Medicine-led study finds
By: Krista Conger From: stanford.edu Treatment of metastatic disease is responsible for nearly one-third of the decrease in annual deaths from breast cancer from 1975 to 2019, according to a Stanford Medicine-led study. Deaths from breast cancer dropped 58% between 1975 and 2019 due to a combination of screening mammography and improvements in treatment, according to a new multicenter study …
ADC Choices Require Discretion in HER2-Negative MBC
By: Kyle Doherty From: onclive.com With multiple antibody drug conjugate (ADC) options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies, according to a presentation by Joshua Z. Drago, MD, MS, during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow® conference.1 “ADCs are being developed …
ctDNA Helps Identify Targets in HR+, HER2- Metastatic Breast Cancer
From: targetedonc.com CASE SUMMARY A 56-year-old, postmenopausal woman presents with a palpable right breast mass with no clinically abnormal axillary lymph nodes. Core biopsy showed the patient had grade II invasive ductal carcinoma (IDC), was estrogen receptor-positive (ER+)/progesterone receptor-positive (PR+), and had HER2 immunohistochemistry (IHC) of 0; Ki-67 was at 33%. Lumpectomy and sentinel lymph node (SLN) biopsy showed a …
New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer
By: By Dr. Chinta Sidharthan From: news-medical.net In a recent study published in the BMJ Journal, a team of scientists from China investigated the safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib, a pan-HER inhibitor, in combination with docetaxel and trastuzumab, and compared it to that of a variety of a …
Dato-DXd Induces Significantly Improved PFS in HR+, HER2- Metastatic Breast Cancer
By: Kristie L. Kahl From: targetedonc.com Treatment with datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared with chemotherapy, in patients with hormone receptor-positive, HER2-low or -negative metastatic breast cancer, according to data from the pivotal phase 3 TROPION-Breast01 trial (NCT05104866) presented at ESMO Congress 2023.1,2 “Overall results support Dato-DXd as a potential …
Zotatifin Triplet May Improve Outcomes Post–CDK4/6 Inhibition in ER+ Breast Cancer
By: Courtney Flaherty From: onclive.com Despite the ever-growing landscape of therapeutics for patients with estrogen receptor (ER)–positive metastatic breast cancer beyond the first line, there is still a substantial need for effective options for those who develop resistance to standard endocrine therapies through multiple mechanisms. Due to its unique mechanism of action, adding the selective eIF4A inhibitor zotatifin (eFT226) to …
No New Safety Concerns Are Identified With Subcutaneous Trastuzumab in HER+ Metastatic Breast Cancer
By: Kyle Doherty From: oncnursingnews.com Subcutaneous trastuzumab (Herceptin) demonstrated a safety profile similar to that of intravenous trastuzumab, according to findings from the final analysis of the phase 3 MetaspHER trial (NCT01810393) published in Clinical Breast Cancer.1 Of note, no new concerns related to prolonged exposure in patients with HER2-positive metastatic breast cancer emerged. During the study treatment period (cycles 1-18), patients …
Jennifer Plichta, MD, on Improved Staging for De Novo Metastatic Breast Cancer
By: Jeff Minerd From: medpagetoday.com A novel prognostic staging system for patients with de novo metastatic breast cancer (dnMBC) reflects improved outcomes for this disease, accurately summarizes prognosis, and facilitates patient-provider communication, researchers reported in the Journal of Clinical Oncology. Although the American Joint Commission on Cancer (AJCC) revised staging guidelines for breast cancer in 2016, “this did not include …